Key Words appetite, metabolism, arousal, narcolepsy, lateral hypothalamus s Abstract Orexin-A and orexin-B are neuropeptides originally identified as endogenous ligands for two orphan G-protein-coupled receptors. Orexin neuropeptides (also known as hypocretins) are produced by a small group of neurons in the lateral hypothalamic and perifornical areas, a region classically implicated in the control of mammalian feeding behavior. Orexin neurons project throughout the central nervous system (CNS) to nuclei known to be important in the control of feeding, sleepwakefulness, neuroendocrine homeostasis, and autonomic regulation. orexin mRNA expression is upregulated by fasting and insulin-induced hypoglycemia. C-fos expression in orexin neurons, an indicator of neuronal activation, is positively correlated with wakefulness and negatively correlated with rapid eye movement (REM) and non-REM sleep states. Intracerebroventricular administration of orexins has been shown to significantly increase food consumption, wakefulness, and locomotor activity in rodent models. Conversely, an orexin receptor antagonist inhibits food consumption. Targeted disruption of the orexin gene in mice produces a syndrome remarkably similar to human and canine narcolepsy, a sleep disorder characterized by excessive daytime sleepiness, cataplexy, and other pathological manifestations of the intrusion of REM sleep-related features into wakefulness. Furthermore, orexin knockout mice are hypophagic compared with weight and age-matched littermates, suggesting a role in modulating energy metabolism. These findings suggest that the orexin neuropeptide system plays a significant role in feeding and sleep-wakefulness regulation, possibly by coordinating the complex behavioral and physiologic responses of these complementary homeostatic functions.
INTRODUCTION
Feeding behavior is dependent upon the integration of metabolic, autonomic, endocrine, and environmental factors coordinated with an appropriate state of cortical arousal (wakefulness). Historically, the hypothalamus has been recognized to play a critical role in maintaining energy homeostasis by integrating these factors and coordinating the behavioral, metabolic, and neuroendocrine responses (Oomura 1980; Bernardis & Bellinger 1993 . In mammals, the neurons of the lateral hypothalamic area (LHA) are particularly important for feeding and behavioral arousal. Animal models with lesions of the LHA exhibit hypophagia, an increased metabolic rate and decreased arousal that frequently leads to death by starvation. Furthermore, they consistently fail to respond to homeostatic challenges such as fasting with appropriate adaptive behavioral and physiologic responses (Bernardis & Bellinger 1996) . Therefore, the LHA has classically been regarded as the hypothalamic "feeding center" and as an important component of the autonomic nervous system with extensive projections within the hypothalamus and throughout the entire neuroaxis. With the ability to influence nuclei throughout the CNS, the LHA appears to be anatomically well placed to coordinate the metabolic, motivational, motor, autonomic, and arousal processes necessary to elicit environmentally appropriate feeding-related behaviors (Bernardis & Bellinger 1993 .
The past 10 years have witnessed a dramatic increase in our knowledge regarding the number of central and peripheral mediators of energy homeostasis and their complex physiologic and neuro-anatomic inter-relationships (for a detailed review of peripheral and central mechanisms of feeding, see Woods et al 1998 , and Salton et al 2000 . An understanding of the complex neural network that controls feeding behavior is emerging from these studies. The regulation of the known hypothalamic neuropeptide mediators are highly influenced by the peripheral lipostat leptin. Principal components of this leptinsensitive network include antagonistic and complementary appetite-stimulating (orexigenic) and appetite-suppressing (anorectic) pathways. Several authors have suggested that the central orexigenic pathways involving neuropeptide Y (NPY), agouti-related peptide (AgRP) and melanin concentrating hormone (MCH) are redundant, or that some of these factors lack physiologic relevance in vivo , Salton et al 2000 . For example, NPY potently increases food consumption when given centrally but Npy-null mutant mice fail to demonstrate a significant feeding phenotype. Anorectic pathways, such as those involving alphamelanocyte stimulating hormone (α-MSH) and leptin appear to be less redundant since null mouse mutants for these factors and their receptors are well described models of obesity , Salton et al 2000 . Still, it is likely that many other central and peripheral mediators of energy homeostasis remain unidentified, and our understanding of the complex interactions among the many feeding-related pathways is still limited.
Until recently, melanin-concentrating hormone (MCH) was the only neuropeptide implicated in feeding regulation known to be produced solely within the LHA.
MCH dose-dependently increases food consumption when administered centrally in rodents. Genetic disruption of the MCH gene in mice results in hypophagia and reduced body weight compared with wild-type littermates (Salton et al 2000 , Shimada et al 1998 . Now, after the discovery of orexin neuropeptides A and B (Greek: Orexis = appetite), two more neuropeptides from the LHA have been identified that mediate feeding behavior and are likely to play a significant role in energy homeostasis.
OREXIN SIGNALING PATHWAY Orexin Neuropeptides
Our group isolated orexin-A and orexin-B while screening high-resolution highperformance liquid chromatography fractions from brain extracts for stimulation of signal transduction in cell lines expressing orphan G-protein-coupled receptors (GPCRs) (Sakurai et al 1998) . Mammalian orexin-A is a 33 amino-acid peptide of 3562 Da with an N-terminal pyroglutamyl residue, C-terminal amidation (both typical of neuropeptides), and two sets of intrachain disulfide bonds (Figure 1) . The primary structure of orexin-A is completely conserved among human, rat, mouse, cow, and pig genera , Dyer et al 1999 . Mammalian orexin-B is a 28-amino acid, C-terminally amidated peptide of 2937 Da with 46% (13/28) amino acid identity to the orexin-A sequence (Figure 1 ). Mouse and rat orexin-B peptides are identical, but human orexin-B has two amino acid substitutions compared with the rodent sequences (Sakurai et al 1998) . Orexins have also been cloned in the amphibian Xenopus laevis and found to have a high amino acid identity with their mammalian counterparts, especially at the carboxyl terminus ( Figure 1 ; Shibahara et al 1999) .
A single gene composed of two exons and an intervening intron encodes the orexin neuropeptides. This structure is conserved within rodent and human genomes (Sakurai et al 1998 . prepro-orexin cDNAs encode 130-residue and 131-residue polypeptides in rat and human neurons, respectively. These polypeptides have typical secretory signal sequences and are cleaved to form mature orexin-A and orexin-B peptides that are post-translationally modified as neuropeptides.
A messenger RNA encoding the same neuropeptide precursor was independently isolated from a hypothalamus-enriched cDNA library by using a differential cloning approach, and the putative encoded peptides were named hypocretins by de . Nucleotide sequence alignment shows that the base-pair sequences of hypocretins-1 and -2 are the same as orexins-A and -B, but that the mature peptides predicted in this report had additional amino acids not found in native orexins. The hypocretin peptides, synthesized according to sequences predicted by de Lecea et al (1998) , are markedly less potent agonists compared with orexins on transfected cells expressing human orexin receptors (Smart et al 2000) . The hypocretins were named for the limited identity of hypocretin-2 (orexin-B) with the gut hormone secretin, but native orexin peptides are, in fact, distantly similar to the bombesin neuropeptide family and not the secretin family (Figure 1 ). Nevertheless, both names are used interchangeably in the literature. Sakurai et al (1998) identified two orexin receptor subtypes, named orexin-1 receptor (OX 1 R) and orexin-2 receptor (OX 2 R), that are structurally similar to other G-protein-coupled neuropeptide receptors. The OX 1 R is the orphan G-proteincoupled receptor used during ligand hunting to first identify and then purify the orexins. A search of the GenBank dbEST database with the OX 1 R amino acid sequence revealed two candidate ESTs. Using PCR, with primers designed from these ESTs, the OX 2 R receptor was discovered and found to have a 64% aminoacid identity with OX 1 R. Competitive radio-ligand binding assays reveal that the orexin receptors have different binding profiles for the respective orexin peptides. The OX 1 R has a 1-order-of-magnitude greater affinity for orexin-A [50% Inhibitory Concentration (IC 50 = 20 nM)] compared with orexin-B (IC 50 = 250 nM). In contrast, orexins-A and -B bind the OX 2 R with equal affinity (IC 50 = 20 nM). Therefore, it appears that the OX 1 R is moderately selective for orexin-A, whereas OX 2 R is a nonselective receptor for both neuropeptide agonists. Evidence from receptor-transfected cell lines and isolated receptor-expressing hypothalamic neurons suggest that the OX 1 R is coupled exclusively to the G q subclass of heterotrimeric G proteins, whereas OX 2 R may couple to G i/o , and/or G q (Sakurai et al 1998; van den Pol et al 1998 ; T Yada, S Muroya, H Funahashi, S Shioda, A Yamanaka, et al, submitted for publication).
Orexin Receptors

Neuroanatomy of the Orexin System
In the rodent CNS, orexin-producing cells (Figure 2 ) are a small group of neurons restricted to the lateral and posterior hypothalamus and perifornical areas (Chemelli et al 1999 , Sakurai et al 1998 . Despite their highly restricted origin, immunohistochemistry studies using orexin antibodies have shown that orexin neurons project widely throughout the entire neuroaxis. Particularly abundant projections are those found in the cerebral cortex, olfactory bulb, hippocampus, amygdala, septum, diagonal band of Broca, bed nucleus of the stria terminalis, thalamus, anterior and posterior hypothalamus, midbrain, brainstem, and spinal cord , van den Pol 1999 . Orexin immunoreactivity is also reported in the enteric nervous system and pancreas (Kirchgessner & Liu 1999) , and orexin mRNA expression has been found in the testes (Sakurai et al 1998) .
In situ hybridization studies with orexin receptor riboprobes demonstrate that orexin receptors are expressed in a pattern consistent with orexin projections, but that they have a marked differential distribution (Marcus et al 2000 , Trivedi et al 1998 . ox1r mRNA is highly expressed in the prefrontal cortex, hippocampus, Figure 2 Orexin neurons are found only in the lateral hypothalamic area and project to the entire central nervous system. Schematic drawing of a sagittal section through the rat brain summarizes the organization of the orexin neuronal system. Abbreviations: 3V, third ventricle; 4V, fourth ventricle; Amyg, amygdala; VLPO, ventrolateral preoptic area; SCN, suprachiasmatic nucleus; PVN, paraventricular nucleus; VMH, ventromedial hypothalamus; ARC, arcuate nucleus; DMH, dorsomedial hypothalamus; LH, lateral hypothalamus; TMN, tuberomamillary nucleus; PPN, pedunculopontine nucleus; LC, locus coeruleus. Modified with permission from T Sakurai (1999) . paraventricular thalamus, ventromedial hypothalamus (VMH), arcuate nucleus (ARC), dorsal raphe nucleus, and locus coeruleus (LC). ox2r mRNA is found in the cerebral cortex, septal nuclei, hippocampus, medial thalamic groups, dorsal and median raphe nuclei, and many hypothalamic nuclei including the tuberomammillary nucleus (TMN), dorsomedial hypothalamus (DMH), paraventricular hypothalamic nucleus (PVN), and ventral premammillary nucleus. Orexin receptor mRNA expression has also been reported in the adrenal gland (Malendowicz et al 1999) , enteric nervous system, and pancreas (Kirchgessner & Liu 1999) . Intracerebroventricular (i.c.v.) injection studies of orexin neuropeptide using Fos as an immunohistochemical marker of neuronal activation demonstrated that the distribution of neurons activated by either orexin-A or orexin-B is similar . The pattern of Fos immunoreactivity is consistent with orexin immunohistochemistry studies and orexin receptor in situ hybridization studies. Areas with the strongest activation include the arcuate nucleus (ARC), PVN, supraoptic nucleus, paraventricular thalamic nucleus, LC, central gray, dorsal raphe, nucleus of the solitary tract, dorsal motor nucleus of the vagus, and suprachiasmatic nucleus. However, no conclusions regarding direct receptor-specific activation can be derived from this study. Furthermore, these studies should be interpreted cautiously since nuclei in close proximity to the ventricular space would be preferentially activated from ventricular delivery, and no conclusions regarding orexin-mediated inhibition of neuronal pathways were obtained. The potential importance of orexin-mediated inhibition is confirmed by the work of van den . These investigators found that orexins increase the release of the inhibitory neurotransmitter γ -aminobutyric acid (GABA), as well as the excitatory neurotransmitter glutamate, by acting directly on axon terminals of neuroendocrine cells in the ARC nucleus.
Orexin neurons also express mRNAs for the orexigenic opioid dynorphin and the secretory marker secretogranin II , and the biosynthesis of these three peptides may be similarly regulated . Immunoreactivity for the appetite stimulating neuropeptide galanin has also been identified in orexin neurons (Hakansson et al 1999) . MCH neurons, like orexin neurons, are found in the LHA and project diffusely throughout the entire neuroaxis . However, definitive immunohistochemistry studies have demonstrated that orexin and MCH neurons are distinct and independent neuronal populations within the LHA (Broberger et al 1998 , Elias et al 1998 .
OREXINS MAINTAIN WAKEFULNESS
The regulation of sleep-wakefulness cycling within the context of circadian and environmental influences is critical for the efficient maintenance of energy homeostasis. In mammals, the sleep-wakefulness cycle can be divided into periods of waking, non-rapid-eye-movement (non-REM), and rapid-eye-movement (REM) sleep on the basis of distinct behavioral and electroencephalographic (EEG) criteria. A role for LHA in sleep regulation was suggested by early animal experiments that showed electrical stimulation of the LHA promoted wakefulness while destruction of the LHA caused somnolence and inattentiveness (Bernardis & Bellinger 1996 , Levitt & Teitelbaum 1975 , Danguir & Nicolaidis 1980a ). More recent studies have identified posterior lateral hypothalamic neurons whose firing rates vary with the sleep-wakefulness cycle (Steininger et al 1999) . Sleep studies in rats found that Fos immunoreactivity in orexin neurons is positively correlated with wakefulness and negatively correlated with the amount of non-REM and REM sleep, suggesting that these neurons are "waking-active" (Estabrooke et al 2000) . They further demonstrated that orexin neuronal activity appears to be under strong circadian control since the temporal relationship with wakefulness and the usual onset of the dark phase, is preserved even under conditions of constant darkness. Fos is also increased after mild sleep deprivation produced by gentle handling, and after administration of wake-promoting stimulants such as modafinil and amphetamine (Chemelli et al 1999 , Estabrooke et al 2000 . I.c.v. administration of orexin-A in rodents dose-dependently increases wakefulness and suppresses non-REM and REM sleep providing further evidence that orexins play a causative role in sleep-wakefulness regulation (Hagan et al 1999) . Orexin i.c.v. injection in rats is also associated with behavioral changes indicative of an aroused state including increased locomotor activity, rearing, grooming, burrowing, searching behaviors, and food consumption (discussed below) (Hagan et al 1999 , Ida et al 1999 , Sakurai et al 1998 .
Two recent reports highlight the importance of orexin signaling in the promotion and consolidation of wakefulness. Our group discovered that orexin neuropeptide knockout mice have a phenotype remarkably similar to the human sleep disorder narcolepsy (Chemelli et al 1999) . And, in a complementary but independent study, Mignot and colleagues found that the genetic defect in a narcoleptic dog model is in the ox2r gene (Lin et al 1999) . Idiopathic narcolepsy is a debilitating, lifelong neurologic disease characterized by excessive daytime sleepiness, cataplexy, and other pathologic intrusions of REM-associated phenomena into wakefulness. The ability of narcoleptic patients to lead normal lives is compromised by frequent involuntary or irresistible daytime "sleep attacks" and sporadic episodes of sudden bilateral skeletal muscle weakness (cataplexy). Cataplexy is often provoked by strong emotion and can be partial or complete (causing collapse to the floor) while consciousness is maintained (Honda 1988) . "Sleep-onset REM periods," REM sleep occurring at or near sleep onset, are pathognomonic for narcolepsy and confirm the clinical diagnosis. The uncontrollable intrusion of REM sleep into wakefulness is thought to form the physiologic basis of narcoleptic symptomatology (Bassetti & Aldrich 1996) . In contrast to animal narcolepsy models, human narcolepsy is rarely familial and is thought to involve environmental factors acting on a genetically susceptible background (Mignot 1998) . The strong association between human leukocyte antigen class II haplotypes DR2 and DQB1*0602 with sporadic human narcolepsy has suggested that an autoimmune process may play a role in the etiology of this disorder (Mignot 1998) .
Several recent studies confirm the contribution of disrupted orexin signaling to the etiology of human narcolepsy. Nishino et al (2000) found that orexin-A was undetected in the cerebrospinal fluid (CSF ) of 7 of 9 narcoleptic patients, but readily and consistently detected in normal controls. Peyron et al (2000) studied human brains and reported that orexin mRNA and peptides are completely absent from narcoleptics but consistently detected in control brains. Futhermore, an unusually severe, early onset case of human narcolepsy is associated with a mutation in the secretory signaling sequence of the orexin locus (Peyron et al 2000) .
Based on behavioral and polysomnographic criteria, orexin knockout mice exhibit a phenotype strikingly similar to human narcoleptics (Chemelli et al 1999) . Homozygous knockout mice have frequent narcoleptic/cataplectic attacks during the dark phase, when mice spend the most time awake and active. EEG/EMG recordings reveal significant disruptions of sleep-wakefulness cycling that are also primarily restricted to the dark phase. Graphs illustrating typical vigilance state cycling (hypnograms) for wild-type and orexin knockout mice are presented in Figure 3 . The orexin-null mouse hypnogram is characterized by frequent direct transitions into REM sleep from wakefulness (arrowheads in Figure 3B ) and marked fragmentation of waking. Quantitative sleep state parameters for orexin knockout mice reveal significantly decreased waking time, increased non-REM and REM sleep time, decreased REM sleep latency, and, perhaps most importantly, a decreased duration of waking episodes during the dark phase.
A ten-year positional cloning effort to find the canine narcolepsy gene recently identified defects in the ox2r gene as the cause of well-characterized autosomal recessive model of narcolepsy in dogs (Lin et al 1999) . Mignot's team found intron deletions in the canine gene that cause defective mRNA splicing and consequent production of non-functional OX 2 R receptors. Our lab has also created mice with targeted disruptions of the ox1r and ox2r receptor genes. Preliminary studies in the receptor knockouts show that, as expected, the ox2r knockout mice have characteristics of narcolepsy. However, the behavioral and electroencephalographic phenotype of the ox2r-null mice is less severe than that found in the orexin neuropeptide knockout mice (Chemelli et al 1999 . Interestingly, the ox1r knockouts do not have any overt behavioral abnormalities and exhibit only increased fragmentation of sleep wakefulness cycles (Kisanuki et al 2000) . Double receptor knockouts (ox1r-and ox2r-null mice) appear to be a phenocopy of the ligand knockout mice (Kisanuki et al 2000) . This suggests that despite the lack of an overt ox1r phenotype, loss of signaling through both receptor pathways is necessary for the severe narcoleptic characteristics of the orexin-null mice.
Cataplexy is frequently observed in dogs and mice with disrupted orexin signaling. Strong, generally positive emotional stimuli such as laughter are known to trigger cataplexy in humans with narcolepsy. This implies that orexin neurons may play a role in the physiologic responses associated with emotions. Orexin neuronal projections to the limbic system, dopaminergic ventral tegmental area, and the basal forebrain cholinergic centers are consistent with this suggestion , Sakurai et al 1998 , Nakamura et al 2000 . Furthermore, neurons controlling cardiovascular responses to emotion map to the perifornical nucleus (Smith et al 1990) , an area of the LHA rich in orexin neurons. Centrally administered orexin-A potently stimulates grooming behavior in rats, a behavior that is often associated with a stress response. Therefore, orexin-A may also promote emotional arousal. Orexin-induced grooming can be partially inhibited by a corticotropin-releasing-factor (CRF ) antagonist further strengthening the assertion that central stress and orexin signaling pathways may be related (Ida et al 2000) . Conversely, orexin signaling is unlikely to increase anxiety because rats exhibit normal exploratory behavior after orexin-A administration (Hagan et al 1999) .
The ascending cortical activating system (ACAS) is a diffuse collection of brainstem nuclei grouped together based on their ability to stimulate cortical arousal and wakefulness. Dense projections from orexin neurons to the ACAS including the histaminergic TMN, noradrenergic LC, serotonergic dorsal raphe, and cholinergic pedunculopontine nucleus provide further anatomic evidence of orexin's important role in sleep-wakefulness regulation (Chemelli et al 1999 . Slice electrophysiology studies of the LC, an important vigilancepromoting nucleus, found that application of orexin-A dose-dependently increases its intrinsic neuronal firing rate (Hagan et al 1999 , Horvath et al 1999b . Taheri et al (2000) found that orexin-A immunoreactivity varies diurnally in the pons, the location of LC, and peaks during the dark phase in rats. This finding appears consistent with a significant role in promoting wakefulness since orexin is most abundant in the region of the LC during the normal waking period in rats. Orexin neurons also innervate the "sleep-active" ventrolateral preoptic area (VLPO). The VLPO is thought to regulate the transition between non-REM and REM sleep by inhibiting the TMN, LC, and median raphe nuclei , Sherin et al 1996 , Sherin et al 1998 . Orexin-A immunoreactivity in the preoptic/anterior hypothalamus, the location of VLPO, also exhibits diurnal variation with the peak occurring during the light phase when VLPO neurons are most active (Taheri et al 2000) . Direct innervation of ventral tegmental dopaminergic neurons (Nakamura et al 2000) and orexin receptor expression in the substantia nigra (Marcus et al 2000) suggest that orexin may modulate dopaminergic involvement in cortical, emotional, and motor arousal. Interestingly, dopamine D1 and D2 antagonists can dose-dependently suppress orexin-induced hyperlocomotor and grooming behaviors (Nakamura et al 2000) .
OREXINS INFLUENCE INGESTIVE BEHAVIORS AND METABOLISM
Feeding
Early lesioning experiments of the LHA consistently caused a syndrome of decreased food and water intake that lowered body weight set-point to about 75%-80% that of sham-operated controls in several species (Teitelbaum & Epstein 1962 , Bernardis & Bellinger 1996 . Complementary electrical stimulation studies of the LHA found that acute stimulation causes hyperphagia and that chronic stimulation can cause obesity. Electrical self-stimulation studies of the LHA demonstrate that the LHA participates in a dopaminergic transmission dependent reward system that is markedly facilitated by food deprivation (Bauco et al 1993 , Fouriezos & Francis 1992 , Carr & Wolinsky 1993 , Goldstein et al 1970 , Bernardis & Bellinger 1996 . This suggests that energy balance may significantly influence the excitability of the LHA feeding circuitry.
Acute injection of orexin-A into the lateral ventricles of fed rats, during the early light phase, significantly and dose-dependently stimulates food consumption (Sakurai et al 1998 , Edwards et al 1999 , Haynes et al 1999 , Yamanaka et al 2000 . Similar experiments with orexin-B were inconsistent, but positive studies found the feeding effects to be shorter-lived than those of orexin-A. This suggests that orexin-A may be more resistant to inactivating peptidases due to its disulfide bonds or that only a subset of the orexin-A feeding pathways (presumably OX 1 R and OX 2 R mediated) may be activated by orexin-B (presumably OX 2 R mediated). It should also be noted that orexin-A is significantly less potent at stimulating food consumption than NPY under the same conditions. However, its duration of action is apparently longer than that of NPY (Sakurai et al 1998) , and the magnitude of the maximum effect of orexins is similar to that of other appetite stimulating peptides such as MCH and galanin (Edwards et al 1999) . The physiologic relevance of feeding effects of orexin is supported by the finding that central administration of a neutralizing anti-orexin antibody significantly and dose-dependently suppresses spontaneous feeding in fasted rats (Yamada et al 2000) . In addition, a selective OX 1 R antagonist can inhibit natural feeding over several days as well as feeding stimulated by fasting or i.c.v. injection of orexin-A (Arch 2000). Furthermore, orexin-A dose-dependently increases gastric acid secretion only when given centrally and with an intact vagus nerve, suggesting a role for orexin in the cephalic phase of digestion and the brain-gut axis (Takahashi et al 1999) . A confounding factor in orexin-feeding studies to date is the potential that these effects may be partly or completely secondary to changes in other unmeasured variables, such as wakefulness.
Circadian processes have a marked influence on feeding behavior and disruptions of normal circadian feeding patterns are well-described effects of LHA lesions (Bernardis & Bellinger 1996) . Interestingly, Haynes et al (1999) found that the feeding response to acute i.c.v. injection of orexin-A is highly dependent on the time of day. They found the largest increase in orexin-stimulated food intake occurred in the early light phase and 6 hr into the dark phase when normal food intake is at a nadir or slowing. Injection of orexin-A at the beginning of the dark phase, when the normal feeding rate is at its highest, had no effect. Similarly, orexin-A was ineffective at increasing intake in the first hour of refeeding after a fast. It seems reasonable to speculate that at the beginning of the dark cycle and immediately after a fast, orexin-stimulated feeding pathways are already maximally activated and therefore unresponsive to additional pharmacologic stimulation by orexin-A.
Chronic infusion of orexin-A over several days disrupts the normal circadian feeding pattern in rats by increasing daytime and decreasing nighttime food intake (Haynes et al 1999 . These studies showed no effect on total daily food intake, adiposity, or body weight. Interestingly, while MCH and galanin yield similar findings, continuous infusion of NPY is the only known neuropeptide that can induce obesity from over-eating . The inability of chronic orexin-A infusions to increase overall food consumption or bodyweight may be due to a circadian variation in the relative responsiveness to exogenous orexin. Food intake is increased during the day when orexin responsiveness is high (and endogenous orexin activity is low), but this daytime hyperphagia may result in counter-regulatory measures that later reduce the drive to eat during periods of relative orexin-insensitivity (when endogenous orexin activity is high) (Haynes et al 1999) . Increased wakefulness is another possible confounding factor: in continuously infused rats, Yamanaka et al (1999) observed increased daytime wakefulness that per se may have resulted in increased feeding.
Nuclei-specific studies performed by Dube et al (1999) found that orexin-A stimulates feeding when microinjected into the PVN, DMN, LHA, and perifornical area of rats. Parallel experiments using orexin-B showed no effect on feeding. Micro-injection into the ARC, VMH, preoptic area, central nucleus of the amygdala, and NTS with either orexin-A or -B did not stimulate feeding . Others, however, have found that orexin-A stimulates feeding in the ARC nucleus (T Yada, S Muroya, H Funahashi, S Shioda, A Yamanaka, et al, submitted for publication). The reasons for this discrepancy are unclear.
There are several examples of spontaneous single-gene mutations and targeted deletions of anorectic signals, satiety factors, and metabolic enzymes that can cause obesity in animal models (for review see Salton et al 2000 . Conversely, mice with null disruptions of orexigenic factors such as NPY, galanin, and β-endorphin typically exhibit normal feeding behavior, body weight, and metabolic homeostasis. Based on these observations, several authors have suggested that there is a robust redundancy among appetite-generating pathways. Disruption of the MCH signaling pathway appears to be the only published exception. Mice with targeted deletions of the MCH gene are hypophagic with decreased body weight and increased oxygen consumption suggesting a hypermetabolic state (Shimada et al 1998) . This pattern of findings is remarkably similar to the LHA lesion syndrome. orexin knockout mice are also significantly hypophagic (Figure 4 ), but have normal body weight suggesting differences in energy homeostasis and metabolic rate (RM Chemelli, unpublished observations). Whether decreased feeding is caused by disruptions in appetite pathways, arousal pathways, or both will need to be examined more closely.
Figure 4
Orexin knockout mice are hypophagic. Data represent 7-day mean food intake adjusted for body weight. Age-and weight-matched group-housed male C57B1/6J-129/SvEv F2 mice were fed freely throughout the study. Despite hypophagia, these mice maintain normal growth curves, suggesting a reduced metabolic rate (RM Chemelli, unpublished observations).
Drinking
Early electrical stimulation studies also suggested that the LHA is a "primary drinking center" (Greer 1955 , Rowland 1976 . LHA lesioning studies cause adipsia that always outlasts aphagia as these animals approach a lower body weight setpoint. Interestingly, animals with lesions become "prandial drinkers;" they only drink when they eat and drink just enough to enable mastication (Bernardis & Bellinger 1996) . Centrally injected orexins increase drinking at doses similar to those that elicit increased feeding (Kunii et al 1999) . This effect is similar in potency to angiotensin II but orexin-stimulated water intake is longer-lasting. These effects are consistent with orexin innervation of the subfornical organ and the area postrema, regions known to be important in fluid homeostasis. In addition, prepro-orexin mRNA levels are upregulated during fluid deprivation (Kunii et al 1999) .
Metabolic, Autonomic, and Endocrine Effects
The LHA is also important in controlling metabolic rate. Animal models with lesions in the LHA consistently become hypercatabolic and remain so, even after they reach a lower body weight set-point (Bernardis & Bellinger 1993 , Powley & Keesey 1970 . The apparent hypermetabolic phenotype of MCH knockout mice is consistent with these findings (Shimada et al 1998) . Conversely, the finding of decreased food intake and normal body weight suggests that orexin knockout mice are likely to be hypometabolic. This is supported by experiments performed by Lubkin & Stricker-Kongrad (1998) who studied the metabolic effects of i.c.v. orexin injection using indirect calorimetry. They found that orexin-A injection during the light phase increases oxygen consumption and the respiratory quotient by an apparent increase in carbohydrate metabolism. Interestingly, the effect on respiratory quotient is dependent on circadian phase because, although oxygen consumption increases, the respiratory quotient decreases when orexin-A was given in the dark phase.
Several studies suggest that orexin neurons may also influence neuroendocrine homeostasis and modulate pituitary hormone release. Orexin neurons project densely to other nuclei within the hypothalamus and have lesser projections to the pituitary . Neuroendocrine cells from the arcuate nucleus, in a slice electrophysiology preparation, demonstrate a dose-dependent increase in inhibitory post-synaptic potentials in response to orexin neuropeptide application . Several studies show changes in pituitary hormone secretion in response to orexin administration. Hagan et al (1999) found that i.c.v. orexin-A significantly decreases prolactin and growth hormone and increases corticosterone plasma levels. Pulsatile luteinizing hormone secretion is also suppressed suggesting a role in the coordination of metabolic and reproductive functions (Pu et al 1998 , Tamura et al 1999 .
Orexin projections to the nucleus of the solitary tract, dorsal motor nucleus of the vagus, and sympathetic neurons in the intermediolateral column of the spinal cord suggest that orexins may modulate autonomic function and participate in the stress response , van den Pol et al 1999 . Both central and peripheral administration of orexin increase plasma levels of corticosterone (Hagan et al 1999 , Malendowicz et al 1999 , and orexins can stimulate corticosterone release directly from adrenocortical cells in vitro (Malendowicz et al 1999) . Furthermore, ox1r and ox2r mRNAs are expressed in the adrenal medulla, suggesting that orexins may modulate systemic epinephrine release and therefore influence vascular tone (Lopez et al 1999) . This proposal is consistent with studies by several investigators who found that injection of orexin dose-dependently increases heart rate and blood pressure (Chen et al 2000 , Samson et al 1999 , Shirasaka et al 1999 . The sympathomimetic effects of orexin may also indirectly influence orexin-mediated changes in oxygen consumption and substrate utilization.
INTERACTION WITH HYPOTHALAMIC FEEDING PATHWAYS
Leptin is an anorectic protein produced and secreted in proportion to adipocyte fat stores and therefore it is commonly referred to as the "adipostat." Exogenously administered leptin can inhibit the increased feeding stimulated by several orexigenic neuropeptides. In experiments to test whether orexin-mediated feeding is sensitive to leptin, Yamanaka et al (A Yamanaka, K Kunii, N Tsujino, I Matsuzaki, K Goto, T Sakurai, submitted for publication) pre-treated rats with leptin at doses that completely inhibit NPY-and galanin-stimulated feeding. They found that leptin only partially inhibited orexin-mediated feeding. The effect of anorectic peptides, thought to mediate leptin effects on food intake, were then examined. Pre-treatment with either CART (cocaine-and amphetamine-related transcript), αMSH (proopiomelanocortin-derived α-melanocyte-stimulating hormone), or GLP-1 (glucagon-like peptide-1), at doses that abolished NPY-induced feeding, again only partially inhibited orexin-induced feeding. These studies suggest that appetite-stimulating pathways involving NPY and galanin are leptinsensitive, while orexin-mediated feeding involves both leptin-sensitive and -insensitive pathways. Because leptin has recently been shown to promote slow wave (delta) at the expense of REM sleep , the effect of leptin on orexin-mediated arousal should be studied.
The ARC nucleus is a major site of leptin-responsive neurons and is regarded as an important "satiety center" on the basis of classic lesioning studies . This nucleus is a complex collection of neurons that express most of the well-described orexigenic and anorectic neuropeptides. Leptin-mediated inhibition of orexigenic NPY/agouti-related protein (AgRP)-coexpressing neurons and excitation of anorectic proopiomelanocortin (POMC)/ CART-coexpressing neurons are thought to underlie the suppression of appetite by leptin (Hakansson et al 1998 . Orexin neurons project to the ARC nucleus and specifically innervate NPY neurons (Horvath et al 1999a) . Reciprocal connections from NPY/AgRP neurons to orexin and MCH neurons in LHA have also been identified (Horvath et al 1999a , Elias et al 1998 . Furthermore, orexin and MCH neurons are also innervated by αMSH-immunoreactive fibers from the ARC (Elias et al 1998) . Orexin neurons may also be directly inhibited by leptin because leptin receptor immunoreactivity and STAT-3, a transcription factor activated by leptin, are found in orexin neurons (Horvath et al 1999a , Hakansson et al 1999 . It seems likely that orexin neuronal activity is influenced directly by leptin, indirectly through down-stream leptin sensitive pathways, and can provide feedback to these same afferent feeding pathways through reciprocal projections.
Fos expression in NPY neurons of the ARC nucleus is induced by i.c.v. injection of orexin, suggesting that orexin-stimulated feeding may occur through NPY pathways , Yamanaka et al 2000 . To test this hypothesis, Yamanaka et al (2000) studied orexin-induced feeding during complete pharmacologic inhibition of NPY-stimulated feeding. They found that orexin-stimulated feeding was only partially inhibited by pre-treatment with a selective NPY Y1 receptor antagonist. This suggests that activation of NPY-mediated feeding pathways is only partially responsible for orexin-stimulated feeding. It is unlikely that these results were confounded by decreased arousal because NPY inhibits arousal-related behaviors (Ida et al 1999) and has been shown to promote non-REM sleep (Steiger et al 1998) . NPY receptor antagonists would therefore be expected to increase arousal and wakefulness. Furthermore, microinjection of orexin-A or -B directly into the ARC nucleus selectively increases feeding without increasing locomotor and stereotypic behaviors associated with i.c.v. orexin (T Yada, S Muroya, H Funahashi, S Shioda, A Yamanaka, et al, submitted for publication). These experiments suggest that orexin-stimulated food intake is not simply due to increased arousal or prolonged wakefulness.
Isolated ARC neurons were studied to determine their responses to orexin and leptin using an in vitro fura-2 microfluorimetry system (T Yada, S Muroya, H Funahashi, S Shioda, A Yamanaka, et al, submitted for publication). Application of orexin-A or -B to POMC neurons decreased cytosolic calcium ([Ca 2+ ] i ) and inhibited [Ca 2+ ] i oscillations with a picomolar sensitivity. This effect had an equimolar sensitivity to orexin-A and orexin-B and was inhibited by pertussis toxin suggesting that it is mediated through an OX 2 R pathway that is coupled to G i and/or G o . Interestingly, many of the POMC neurons inhibited by orexin were excited by picomolar concentrations of leptin. In contrast, arcuate NPY neurons are inhibited by leptin and excited by orexin-A and -B, with orexin-B 100-fold less potent than orexin-A. Selective inhibitors of phospholipase C, protein kinase C, and inositol tri-phosphate-dependent Ca 2+ channels block these excitatory effects suggesting the involvement of OX 1 R signaling through a G q -coupled pathway.
The VMH is another important component of the "satiety center" and is characterized by a high density of glucose and insulin-responsive neurons (Oomura & Kita 1981) . Although orexin neurons project to the VMH , no feeding response was found by Dube et al (1999) when either orexin-A or -B was microinjected into this site. VMH neurons are, however, inhibited by orexin and excited by leptin in vitro (T Yada, S Muroya, H Funahashi, S Shioda, A Yamanaka et al, submitted for publication). The molecular antagonism between orexin and leptin within the satiety-promoting neurons of the VMH appear to mimic the opposing functions of the LHA and VMH in feeding regulation (Bernardis & Bellinger 1996) .
There is considerable evidence to support a role for orexin in directly stimulating food intake and in coordinating the orexigenic and anorectic feeding pathways of the ARC and VMH nuclei to increase feeding. The antagonism between orexin and leptin-mediated effects in these nuclei is consistent with a model in which orexin-stimulated feeding occurs partially within the context of pathways inhibited by leptin. The potential executive function of orexin in coordinating the known hypothalamic feeding pathways is exemplified by its unique ability to provide simultaneous stimulation of orexigenic (OX 1 R-mediated) and inhibition of anorectic (OX 2 R-mediated) feeding circuits. It is unknown whether orexin signaling mechanisms identified in the ARC and VMH nuclei, characterized by inputs that are both excitatory (OX 1 R) and inhibitory (OX 2 R), are generalizable. However, these mechanisms may provide a model of orexin action at other sites.
REGULATION OF OREXIN NEURONS
The LHA receives innervation from much of the neuroaxis and can also be influenced by actively transported peripheral factors, such as leptin, insulin, and other hormones, as well as diffusible factors including glucose, electrolytes, amino acids, and peptides (Bernardis & Bellinger 1996) . Therefore the regulation of orexin neurons is potentially complex. Because of orexin's restriction to the LHA, and its early association with feeding (Sakurai et al 1998) , most of the work on defining molecular regulatory mechanisms has focused predominantly on feeding and metabolism rather than on pathways involving sleep and wakefulness.
Circadian Influences
Orexin neurons are significantly influenced by circadian processes because Fos studies indicate that orexin neurons are primarily "waking active" (Estabrooke et al 2000) , and circadian feeding patterns are disrupted by chronic central orexin-A injection (Haynes et al 1999) . The suprachiasmatic nucleus (SCN), the CNS circadian oscillator, appears to play a prominent role in controlling diurnal feeding patterns (Zucker & Stephan 1973) . The SCN projects to most of the hypothalamus including the LHA, and SCN lesions eliminate the circadian patterns of sleepwakefulness and food intake as well as the circadian electrical activity of many LHA neurons (Bernardis & Bellinger 1996 , Edgar et al 1993 . The retino-geniculohypothalamic tract, a source of photic information to the SCN, projects to the LHA and may influence circadian activity in the LHA (Mikkelsen 1990 ). Interestingly, Kurumiya & Kawamura (1991) found that the LHA has a weak oscillatory capacity of its own when the SCN is lesioned. Although orexin activates SCN neurons , direct SCN and/or retino-geniculo-hypothalamic efferents to orexin neurons have not yet been reported. The SCN may also indirectly influence orexin neurons through other hypothalamic and thalamic nuclei that in turn project to the LHA. The paraventricular thalamic nucleus, for example, receives input from the SCN, and the paraventricular thalamic nucleus projects to the LHA (Watts et al 1987 , Moga et al 1995 . Spontaneous activity of glucose-sensitive LHA neurons, that probably include orexin neurons (discussed below), exhibit a distinct circadian firing pattern (Schmitt 1973) , suggesting that metabolic and circadian factors influence these neurons. It is unclear whether orexin signaling pathways secondarily mediate circadian feeding and sleep patterns based on SCN signals, or if circadian orexin activity is just an epi-phenomenon of these processes. The latter seems more likely though, because daytime sleep patterns are unaffected (Chemelli et al 1999) and diurnal variation in food intake is intact (RM Chemelli, unpublished observations) in orexin knockout mice.
Nutritional and Visceral Satiety Signals
The LHA reward system is modulated by inhibitory signals from the VMH (Margules & Olds 1962) and it is highly dependent on nutritional state, demonstrating marked potentiation following food deprivation (Carr & Wolinsky 1993 , Goldstein et al 1970 . LHA neuronal activity is suppressed by elevated blood glucose suggesting short-term nutrient sensing. In contrast, VMH neurons are excited by glucose, consistent with the antagonistic roles of the LHA and VMH in feeding regulation (Bernardis & Bellinger 1996) . LHA neurons respond to the presence of food in the gut partly as a result of vagally transmitted afferent intestinal signals that are relayed through the nucleus of the solitary tract (Bernardis & Bellinger 1996) .
Orexin neurons are activated by acute hypoglycemia. Bahjaoui-Bouhaddi et al (1994a) found that insulin, given to acutely lower blood glucose levels in rats, caused a marked increase in Fos-immunoreactivity in LHA neurons now known to express orexin (recently confirmed in Moriguchi et al 1999) . When insulin and glucose were given together so that euglycemia was maintained, no increase above baseline Fos levels was found. This, in combination with the report that insulin receptor mRNA is not expressed in the LHA (Marks et al 1990) , suggest that insulin is unlikely to act directly on these neurons. Also, it is unlikely that reduced plasma osmolarity is a confounding factor in these experiments because there were no significant differences in plasma osmolality between the control and experimental groups. Insulin-induced hypoglycemia does not increase Fos in MCH neurons (Bahjaoui-Bouhaddi et al 1994b) , suggesting that the mechanisms regulating orexin and MCH neurons are different. Cai et al (1999) performed a detailed study of orexin mRNA expression in rats after physiologic and pharmacologic manipulations designed to stimulate food intake through different mechanisms. These authors fasted rats for 48 hours and found that orexin mRNA levels significantly increased over controls, accompanied by decreases in serum leptin and glucose. No significant difference in orexin mRNA levels were found when rats were restricted to 50% of their usual daily intake for six days. Serum leptin and glucose levels at the end of this experiment were 38% and 83% of control values, respectively. These starvation studies suggest that orexin expression increase markedly in response to acute metabolic challenges, but approach normal after sub-acute stresses when compensatory metabolic processes are likely to intervene (glucose and leptin returning toward baseline values). These authors then studied rats after 6 hours of acute hypoglycemia and after six days of chronic hypoglycemia induced by subcutaneous insulin injections. A significant increase in orexin mRNA expression was found after acute hypoglycemia when rats were food-deprived after insulin injection, but no change was seen when they were allowed to feed freely. Leptin and glucose levels were 228% and 49% vs. 228% and 17% of control values in the freely fed vs. fooddeprived conditions, respectively. An increase in orexin mRNA expression that approached significance was observed after chronic hypoglycemia and freely-fed conditions, with serum leptin and glucose levels 288% and 47% of controls. These authors identified subnormal plasma glucose levels and absence of food intake as key factors associated with increased orexin mRNA expression. They further suggested that orexin neurons may belong to a glucose-sensitive sub-population of LHA neurons that are stimulated by falls in serum glucose and inhibited by vagally-mediated prandial signals, such as gastric distension and/or rising portal venous glucose concentrations (Bernardis & Bellinger 1996) . These hypoglycemia studies also suggest that orexin neurons are more responsive to nutrient depletion (hypoglycemia) than nutrient excess signals (hyperleptinemia) when faced with antagonistic influences.
orexin expression may also be regulated by changes in serum osmolarity. orexin mRNA is significantly upregulated after 48 hours of water deprivation and Fos immunoreactivity is increased under hyperosmotic conditions (Kunii et al 1999) . However, no studies of whether orexin neurons are directly osmosensitive are available.
Leptin and Hypothalamic Feeding Peptides
The LHA receives afferent projections from many CNS areas known to be important in energy homeostasis (Bernardis & Bellinger 1996) . Broberger et al (1998) and Elias et al (1998) have presented convincing neuroanatomic evidence of extensive reciprocal innervation between the leptin-sensitive feeding pathways of the ARC nucleus and orexin neurons of the LHA. Leptin receptor immunoreactivity has also been identified in orexin neurons, raising the possibility of leptin directly influencing these neurons (Horvath et al 1999a , Hakansson et al 1999 . Interestingly, leptin was recently demonstrated to inhibit LHA reward mechanisms in a self-stimulation paradigm (Fulton et al 2000) .
Leptin regulates the expression of many orexigenic and anorectic signals . Lopez et al (2000) found that leptin injection suppresses the welldescribed fasting-induced increase in orexin mRNA expression in rats. They also found increased ox1r receptor mRNA expression with fasting that was suppressed by leptin treatment. No change in ox2r receptor mRNA expression was detected in either fasted or leptin-treated conditions. These results suggest that leptin influences orexin gene expression in food-restricted rats and that the OX 1 R signaling pathway is leptin-sensitive and involved in the efferent response to fasting. Interestingly, no effect on orexin, ox1r, or ox2r mRNA expression was found after leptin-treatment under freely fed conditions. Genetic mouse models of obesity have been instrumental in identifying and characterizing many hypothalamic feeding pathways. Deficient leptin signaling causes hyperphagia, abnormal glucose utilization, infertility, and early-onset obesity in ob/ob and db/db mice. The leptin gene has a nonsense mutation in the ob/ob mouse whereas the db/db mouse has an inactivating mutation in the leptin receptor gene (Zhang et al 1994 , Chen et al 1996 . In lethal yellow (A y /a) mice, a genetic rearrangement causes ubiquitous over-expression of the coat color signaling protein agouti (Miller et al 1993) . Peripheral over-expression causes the characteristic yellow coat color while central over-expression antagonizes α-MSH at the melanocortin-4 receptor (MC4-R), mimicking the native actions of hypothalamic AgRP (Barsh 1999 , Salton et al 2000 . Unregulated chronic antagonism of the anorectic neuropeptide α-MSH causes a dominantly inherited maturity onset obesity syndrome associated with hyperphagia, hyperinsulinemia, hyperglycemia, and hyperleptinemia (Salton et al 2000 , Maffei et al 1995 . Orexin and MCH neurons are strongly innervated by leptin-sensitive AgRP, α-MSH, and NPY neurons , and mcr-4 mRNA is highly expressed within the lateral hypothalamus (Elias et al 1998) .
Studies of Mch, Npy, and orexin gene expression in these mouse models of obesity suggest that orexin is regulated in a manner opposite to that of MCH and NPY. In freely-fed ob/ob, db/db, and A y /a mice, Mch and Npy expression are upregulated compared with normal controls (Qu et al 1996 , Stephens et al 1995 , Kesterson et al 1997 , whereas orexin expression is decreased (Yamamoto et al 1999 . This suggests that the MCH and NPY pathways are normally inhibited by leptin and that increased Mch and Npy expression may contribute to hyperphagia in these mice. This is supported by decreased food intake and partial amelioration of obesity in Npy-null, ob/ob double mutants (Erickson et al 1996 , Salton et al 2000 . The finding of decreased orexin expression in these obese mutants is contrary to a model in which orexin is predicted to be upregulated if it is directly inhibited by leptin. It is however, consistent with upregulation of leptin-sensitive NPY and MCH efferents that cause hyperphagia and contradictory signals of nutritional excess, such as hyperglycemia, increased free fatty acids, and visceral satiety afferents that consequently override the lack of leptin signaling and decrease orexin expression. Regardless of the specific mechanisms involved, it is clear that orexin is unlikely to contribute to the characteristic hyperphagia in these mouse models of obesity. It is intriguing to speculate, however, that decreased orexin expression contributes to the decreased metabolic rate that is believed necessary to explain the extreme obesity of these genetic models since it cannot be explained on grounds of increased food intake alone.
Apparently contradictory results have been obtained from studies examining orexin expression when ob/ob and A y /a mice are fasted. Yamamoto et al (1999) found that orexin expression is increased in ob/ob mice food restricted for 2 weeks compared with freely fed controls. Whereas Hanada et al (2000) found that orexin mRNA expression was unchanged in A y /a mice fasted for 48 hours despite a marked improvement in hyperglycemia. Although different experimental methods (food restriction versus fasting) may partially explain these results, these models are not directly comparable because ob/ob mice lack leptin while A y /a mice are hyperleptinemic. In the absence of leptin (ob/ob mice) and with concurrent signals of nutritional depletion, such as falling glucose and decreased visceral satiety afferents, upregulation of orexin in food-restricted ob/ob mice makes physiologic sense. Conversely, persistent marked hyperleptinemia accompanied by normalization of plasma glucose might not lead to changes in orexin expression in the fasted A y /a mouse. It is also possible that orexin expression in mouse models of obesity might be a reflection of obesity-induced changes in wakefulness that can be influenced by fasting, but these studies have not been performed.
DISCUSSION
Feeding behavior is critically dependent on appropriate sleep-wakefulness cycling at environmentally advantageous times and in response to homeostatic needs. While feeding and sleep are mutually exclusive behaviors, wakefulness, with increased sensory awareness and motor activity, is required for successful feeding. The relationship among waking, feeding, and environment are highly species dependent. While humans consolidate waking and feeding cycles during the daytime, rodents are awake and feed primarily at night. It can be argued that the balance between food availability and the relative risks of predation were the evolutionary driving forces behind these divergent behavioral patterns. Similarly, during periods of nutritional depletion, central mechanisms capable of augmenting wakefulness and therefore feeding opportunities within the proper circadian phase would confer an advantage. Because of the co-dependency between sleep-wakefulness and feeding, stressors that primarily affect one very often affect the other. Indeed, comorbid disturbances of sleep, appetite, and metabolism are well-described symptoms of obesity, anorexia nervosa, depression, and Cushings disease (Crisp et al 1970 , Crisp et al 1971 , Fleming 1989 , Wurtman & Wurtman 1995 , Shipley et al 1992 .
Substantial evidence is accumulating to support the hypothesis that pathologic disruption of orexin signaling causes narcolepsy in humans, mice, and dogs. Several studies suggest that altered energy homeostasis may accompany narcolepsy in these species. Honda et al (1986) found an increased incidence of non-insulin-dependent diabetes mellitus in an adult Japanese population with narcolepsy. Another study found lower daily caloric intake in narcoleptics compared with matched controls, and that the difference was due primarily to reduced carbohydrate intake (Lammers et al 1996) . Schuld et al (2000) found that narcoleptic patients have an increased body mass index suggesting a tendency toward obesity. Further support for the proposed link between altered metabolism and narcolepsy include many case reports of obesity in pediatric narcolepsy (Dahl et al 1994 , Allsopp et al 1992 , Kotagal et al 1990 . The finding of decreased caloric intake combined with an increased body mass index suggest that narcoleptics have reduced energy expenditure or metabolic rate. Interestingly, orexin knockout mice consume significantly less food (Figure 4 ) but maintain the same body weight as young age-matched littermates suggesting differences in energy homeostasis and metabolic rate (RM Chemelli unpublished observations).
No feeding or metabolic abnormalities have been reported in the ox2r-null dog model of narcolepsy. While this may be explained by a lack of surveillance for a subtle phenotype, it may indicate that the OX 1 R-signaling pathway is more important in orexin-mediated energy homeostasis. Several lines of evidence support this hypothesis: There is a marked differential expression pattern of orexin receptors in the CNS, and importantly, a high density of OX 1 Rs are found in the ARC and VMH nuclei of the hypothalamus (Marcus et al 2000 , Trivedi et al 1998 . An OX 1 R-selective antagonist can inhibit orexin-mediated feeding and natural feeding for several days (Arch 2000). And, Lopez et al (2000) found increased ox1r expression in rats fasted for 48 hours and that this response could be ameliorated by leptin, but there was no change in ox2r expression. It is clear that further study of narcoleptic patients and animal models will be important to uncover the physiologic mechanisms underlying these metabolic changes.
Researchers have long recognized that fasting alters sleep-wakefulness patterns in several species (Borbely 1977 , Danguir & Nicolaidas 1979 , Faradji et al 1979 , Rashotte et al 1998 . These investigators found that food deprivation increases waking, decreases non-REM, and markedly reduces REM sleep times. Interestingly, these changes occur only during the normal circadian feeding period of the respective species, except in profound starvation when increased wakefulness extends into the normal sleep period. The magnitude of the changes in wakefulness and non-REM sleep diminish as food deprivation is prolonged, but the striking REM suppression continues. The magnitudes of the fasting-induced changes in vigilance states are also highly dependent on prior nutritional state. Danguir and Nicolaidis (1979) found highly significant increases in waking and reductions in non-REM and REM sleep time in fasted lean rats (240-250 g) but minimal changes in fasted obese rats (300-380 g). The fasting-induced changes found in the lean rats could be reversed by glucose infusion, suggesting that homeostatic sensing of nutritional depletion rather than absence of food in the gut was the critical factor. Conversely, these authors also found that meal size is positively correlated with the subsequent duration of REM and non-REM sleep. In summary, these results suggest that acute reductions in energy substrate availability (e.g., glucose, free fatty acids, and amino acids) stimulate increased waking time, thus presumably increasing the chance of feeding opportunities. The magnitude of this effect is highly dependent upon endogenous energy reserves (possibly through leptin as an indicator of fat stores and metabolic state). And, as food deprivation is prolonged, compensatory mechanisms that conserve energy are engaged and energetically costly increases in wakefulness diminish. It is interesting to speculate that the persistent suppression of REM may also increase feeding opportunities by shifting sleep-rest periods into vigilance states with increased sensory arousal and motor tone.
The regulation of both sleeping and feeding behaviors in mammals is thought to result from the integration of homeostatic and circadian influences (Borbely 1998 . Sleep is promoted homeostatically by prior wakefulness (Borbely 1998) , and biologically active "sleep factors" such as adenosine (Porkka-Heiskanen 1997) have been identified that accumulate in the brain during wakefulness and dissipate during sleep. Similarly, feeding behavior and central metabolic control are regulated homeostatically by prior nutritional state. Acute systemic state is mirrored by circulating metabolites, including glucose, free fatty acids, and amino acids, whereas long-term energy reserves are typically reflected in circulating leptin levels . These homeostatic mechanisms may indicate that the central regulation of both sleep and feeding behaviors is "ischymetric," defined as depending on the rate and degree of utilization of circulating metabolites at the cellular level (Danguir & Nicolaidis 1980b , Nicolaidis & Even 1992 . Indeed, there is substantial evidence to suggest that the LHA is an important site for the ischymetric regulation of feeding-related behaviors (Bernardis & Bellinger 1996) . Furthermore, the LHA is increasingly recognized as an important center for sleep-wakefulness regulation based on neuroanatomic , physiologic (Bernardis & Bellinger 1996 , Levitt & Teitelbaum 1975 , Danguir & Nicolaidis 1980a , Steininger et al 1999 , and recent molecular genetic findings (Chemelli et al 1999 , Lin et al 1999 , Peyron et al 2000 . It seems likely that the LHA plays a significant role in coordinating these processes because fasting-induced changes in sleep are highly dependent on endogenous energy stores (Danguir & Nicolaidis, 1979) , and non-REM sleep is promoted by feeding neuropeptides such as leptin, galanin, and NPY , Steiger et al 1998 . In addition to homeostatic influences, the LHA is also anatomically positioned to integrate circadian rhythms from the SCN (Bernardis & Bellinger 1996 , Edgar et al 1993 and photic information via the retino-geniculo-hypothalamic tracts (Mikkelsen 1990) .
Orexin neurons have the requisite anatomic connections, physiologic effects, interactions with hypothalamic feeding pathways, and regulation by circadian and nutritional factors to suggest that they may be an important cellular and molecular link in the integration of sleep and energy homeostasis ( Figure 5 ). Efferent and afferent innervation of orexin cells suggest interactions between these cells and important feeding centers in the ARC and VMH nuclei, arousal and sleepwakefulness centers in the ACAS and VLPO, sympathetic and parasympathetic nuclei, dopaminergic motor centers, and the limbic system. Numerous studies Figure 5 Model of orexin function in the coordination of energy and sleep homeostasis. Peripheral metabolic signals, leptin, and circadian rhythms influence orexin neuronal activity. Orexin neurons stimulate leptin-sensitive and -insensitive targets to promote appetite and the cephalic phase of digestion. Orexins increase cortical arousal and promote wakefulness through the ascending cortical activating system (ACAS) and other sleep-related nuclei. Stimulation of dopaminergic, limbic, and cholinergic centers by orexins can modulate reward systems, motor activity, and emotional arousal. Endocrine function is influenced by orexin efferents within hypothalamic and pituitary sites. See text for details. Abbreviations and symbols: VMH, ventromedial hypothalamus; GRNs, glucose-responsive neurons; POMC, pro-opiomelanocortin; AgRP, agouti-related protein; NPY, neuropeptide Y; LHA, lateral hypothalamic area; VLPO, ventrolateral preoptic area; GABA, γ -aminobutyric acid; TMN, tuberomamillary nucleus; HA, histamine; LC, locus coeruleus; NE, norepinephrine; 5-HT, serotonin; ACh, acetylcholine; DA, dopamine.
have documented that acute orexin injection dose-dependently increases arousalassociated behavioral and physiologic process including food-intake, waking time, motor activity, and metabolic rate, as well as heart rate and blood pressure. It is unlikely, however, that orexin-signaling plays a significant role in long-term "lipostat" mechanisms since chronic administration fails to increase body weight, total daily food intake, or adiposity. Furthermore, it is likely that orexin-mediated food intake results partly from stimulation of ARC feeding pathways such as those involving NPY. The increased expression of Npy and Mch and decreased expression of orexin found in hyperphagic mouse models of obesity are consistent with this hypothesis. Fasting studies in normal and fat-mutant mice suggest that orexin neurons are more responsive to acute changes in energy substrate availability than endogenous energy stores. The potential role of orexin as a barometer of acute energy homeostasis is further exemplified by its upregulation when integrating contradictory metabolic signals such as hypoglycemia in the face of hyperleptinemia. The strong "waking active" character of orexin neurons also reinforces the hypothesis that orexin signaling is important in the acute regulation of energy homeostasis: short-term changes in substrate availability likely lead to increased orexin neuronal firing that in turn increases sensory arousal, wakefulness, motor activity, and substrate mobilization from energy stores, while stimulating and reinforcing hypothalamic feeding pathways.
The orexin neuropeptide signaling system is an important central pathway that promotes adaptive behavioral and physiologic responses in response to metabolic and environmental signals. During periods of nutritional depletion, orexin-induced increases in arousal and reinforcement of appetite/feeding pathways may be an evolutionarily conserved mechanism that helps to ensure survival. In summary, the orexin neuropeptide system plays a significant role in coordination of feeding and sleep-wakefulness regulation, probably by coordinating the complex behavioral and physiologic responses of these complementary homeostatic functions.
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